Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs

BACKGROUND: Geographic variation in the use of prescription drugs, particularly those deemed harmful by the FDA, may lead to variation in patient exposure to adverse drug events. One such drug is the glucose-lowering drug rosiglitazone, for which the FDA issued a safety alert on May 21, 2007, follow...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Manag Care Spec Pharm
Main Authors: Ahuja, Vishal, Sohn, Min-Woong, Birge, John R., Syverson, Chad, Budiman-Mak, Elly, Emanuele, Nicholas, Cooper, Jennifer M., Huang, Elbert S.
Format: Artigo
Jezik:Inglês
Izdano: Academy of Managed Care Pharmacy 2015
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861222/
https://ncbi.nlm.nih.gov/pubmed/26679970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2015.21.12.1214
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki